tiprankstipranks
Trending News
More News >
Kirin Holdings Company Limited (JP:2503)
:2503

Kirin Holdings Company (2503) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Kirin Holdings Company

(OTC:2503)

Rating:63Neutral
Price Target:
¥2,149.00
▲(8.78%Upside)
Kirin Holdings scores 63, driven by robust financial performance and moderate valuation. However, technical indicators reflect a lack of bullish momentum, and high P/E suggests potential overvaluation, balancing the attractive dividend yield.
Positive Factors
Business Growth Strategy
Kirin is focusing on Health Science as a key earnings driver, aiming to turn a loss into a significant profit by 2027.
Regional Expansion
Growth in the APAC region is expected due to improvements in beverage profit structures and the expansion of Blackmores and FANCL brands.
Negative Factors
Financial Performance
Kirin reported a disappointing Q1 top line whichever way it was cut, with operating profit coming in well below expectations.
Pharmaceutical Segment
The pharmaceutical segment is likely to see further declines in profitability as Kirin increases R&D spending to expand its drug pipeline.

Kirin Holdings Company (2503) vs. iShares MSCI Japan ETF (EWJ)

Kirin Holdings Company Business Overview & Revenue Model

Company DescriptionKirin Holdings Company, Limited is a diversified Japanese company primarily engaged in the beverage, food, and pharmaceutical sectors. Established in 1907, Kirin has grown to become a leading player in the global beverage industry, producing a wide range of products including beer, wine, soft drinks, and dairy products. The company also has a significant presence in the pharmaceutical industry, developing and manufacturing a variety of health-related products. Kirin's operations are spread across multiple countries, making it a prominent international brand.
How the Company Makes MoneyKirin Holdings Company generates revenue through multiple streams, with its core income derived from the production and sale of beverages, including alcoholic beverages like beer and wine, as well as non-alcoholic beverages such as juices and soft drinks. The company also earns substantial revenue from its pharmaceutical division, where it develops and sells pharmaceuticals and health-related products. Kirin's diversified portfolio allows it to benefit from various markets, and its strategic partnerships and joint ventures, such as those with other beverage companies and pharmaceutical firms, enhance its market reach and profitability. Additionally, Kirin invests in innovative product development and marketing strategies to maintain and grow its customer base, contributing to its overall earnings.

Kirin Holdings Company Financial Statement Overview

Summary
Kirin Holdings demonstrates a commendable financial position characterized by steady revenue and profit growth, efficient operations, and robust cash flows. The balance sheet shows a reasonable debt level relative to equity, but the increasing debt trend should be monitored. While profitability margins are stable, optimizing net margins and improving free cash flow conversion could enhance overall financial health. Kirin Holdings remains well-positioned within the alcoholic beverages industry, with opportunities for further strengthening.
Income Statement
76
Positive
Kirin Holdings exhibits a strong financial performance with its TTM gross profit margin at 45.77% and a net profit margin of 2.38%. The company shows a healthy revenue growth rate of 6.03% from 2024 to 2025, indicative of a solid market position. The EBIT margin at 7.87% and EBITDA margin at 12.77% for TTM highlight operational efficiency but suggest room for improvement in net profitability. Overall, the income statement reflects steady revenue and profit growth, though with modest net income margins.
Balance Sheet
68
Positive
Kirin Holdings maintains a balanced financial structure with a debt-to-equity ratio of 0.94, indicating manageable leverage. The return on equity (ROE) is 5.13%, showing moderate returns for shareholders. An equity ratio of 33.89% indicates a fair amount of shareholder equity compared to total assets. While the company has a robust asset base, its rising debt levels warrant careful monitoring to avoid increased financial risk.
Cash Flow
72
Positive
The cash flow statement reveals a positive trajectory with a free cash flow growth rate of 54.44% from 2024 to 2025. The operating cash flow to net income ratio of 3.76 demonstrates strong cash generation ability relative to earnings. However, with a free cash flow to net income ratio of 0.31, there is room for improvement in translating profits into free cash flows. The company showcases healthy operational cash flows but faces challenges in converting those effectively into free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.06T2.34T2.13T1.99T1.82T1.85T
Gross Profit915.58B1.07T920.79B905.71B822.84B803.88B
EBITDA225.70B253.42B294.80B260.36B150.70B189.23B
Net Income130.13B58.21B112.70B111.01B59.79B99.84B
Balance Sheet
Total Assets3.26T3.35T2.87T2.54T2.47T2.46T
Cash, Cash Equivalents and Short-Term Investments122.52B127.19B140.34B96.44B157.40B169.62B
Total Debt1.03T857.57B733.08B523.12B551.47B642.64B
Total Liabilities1.87T1.82T1.44T1.29T1.32T1.36T
Stockholders Equity1.11T1.18T1.13T980.02B894.18B838.58B
Cash Flow
Free Cash Flow0.0062.26B89.40B37.08B132.97B71.81B
Operating Cash Flow0.00242.84B203.21B135.56B219.30B164.84B
Investing Cash Flow0.00-329.38B-226.09B-10.40B-56.41B-115.98B
Financing Cash Flow0.0058.13B35.91B-167.84B-180.46B-52.47B

Kirin Holdings Company Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1975.50
Price Trends
50DMA
2037.48
Negative
100DMA
2034.79
Negative
200DMA
2035.02
Negative
Market Momentum
MACD
-10.04
Positive
RSI
37.04
Neutral
STOCH
9.32
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2503, the sentiment is Negative. The current price of 1975.5 is below the 20-day moving average (MA) of 2007.76, below the 50-day MA of 2037.48, and below the 200-day MA of 2035.02, indicating a bearish trend. The MACD of -10.04 indicates Positive momentum. The RSI at 37.04 is Neutral, neither overbought nor oversold. The STOCH value of 9.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2503.

Kirin Holdings Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥3.96T56.618.89%2.02%6.35%-17.08%
71
Outperform
$2.86T14.807.40%2.80%4.38%13.44%
68
Neutral
¥196.23B21.848.29%2.32%4.97%2.34%
67
Neutral
¥1.40T15.517.61%2.65%3.98%0.28%
67
Neutral
¥861.31B16.636.71%3.19%4.39%2.40%
64
Neutral
$553.08B101.142.87%0.73%2.69%-47.13%
63
Neutral
$1.62T28.244.91%3.70%9.00%-57.41%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2503
Kirin Holdings Company
1,984.50
-49.20
-2.42%
JP:2502
Asahi Group Holdings
1,847.00
20.47
1.12%
JP:2587
Suntory Beverage & Food
4,469.00
-902.63
-16.80%
JP:2802
Ajinomoto Co
3,950.00
961.00
32.15%
JP:2269
Meiji Holdings Co
3,115.00
-415.89
-11.78%
JP:2501
Sapporo Holdings
6,964.00
906.05
14.96%

Kirin Holdings Company Corporate Events

Kirin Holdings Strengthens Board with New Independent Directors
Feb 27, 2025

Kirin Holdings Company has announced the nomination of several experienced individuals as Independent Non-executive Directors and Audit & Supervisory Board Members, aiming to enhance its corporate governance and strategic oversight. The newly appointed directors bring extensive expertise in areas such as pharmaceuticals, international business, corporate governance, and legal affairs, which are expected to contribute to the company’s growth and value enhancement, particularly in the health science domain.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025